Document Detail

High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases.
MedLine Citation:
PMID:  10354024     Owner:  NLM     Status:  MEDLINE    
High-dose intravenous immune globulin (IVIG) is used to treat a wide variety of autoimmune diseases. We report our experiences of its use in a retrospective study of 14 patients with autoimmune blistering diseases, namely epidermolysis bullosa acquisita (EBA), two; bullous pemphigoid (BP), two; pemphigoid gestationis (PG), one; nodular pemphigoid, two; and pemphigus vulgaris (PV), seven. Two patients with refractory EBA improved following regular courses of IVIG given as monotherapy. IVIG had a steroid-sparing effect in 10 patients with PV, BP and PG. However, the clinical effects were transient and of variable intervals, and repeated courses of IVIG were required. The rapid actions of IVIG were of particular benefit in two patients with extensive, rapidly progressive PV and in one patient with BP in whom swift disease control was required. In such cases, when rapid disease control is paramount, we recommend IVIG used in conjunction with conventional treatments as a safer and less invasive alternative to plasmapheresis. IVIG was ineffective in two patients with nodular pemphigoid. Analysis of indirect immunofluorescence (IIF) titres before and after IVIG showed that a fall in titre occurred after 78% of treatments and was observed in all disease groups. However, like the clinical improvements, the falls in IIF titres were transient and of variable interval, and titres rose back to pretreatment levels in all but one patient. IVIG appears to be beneficial under certain circumstances for the treatment of autoimmune blistering diseases but controlled trials are required to define its therapeutic role further.
K E Harman; M M Black
Related Documents :
2773054 - Gastrointestinal malignancies in a young tropical african population.
16700784 - Pemphigus in the mediterranean region of turkey: a study of 148 cases.
6735764 - Regional hyperthermia in the treatment of clinically advanced, deep seated malignancy: ...
25388964 - Scd163 in aosd: a biomarker for macrophage activation related to hyperferritinemia.
3728314 - Hemodynamic and electrophysiologic results of the senning procedure for transposition o...
7306614 - Acute metabolic response to cold exposure in unipolar and bipolar ii patients.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The British journal of dermatology     Volume:  140     ISSN:  0007-0963     ISO Abbreviation:  Br. J. Dermatol.     Publication Date:  1999 May 
Date Detail:
Created Date:  2000-05-04     Completed Date:  2000-05-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0004041     Medline TA:  Br J Dermatol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  865-74     Citation Subset:  IM    
St John's Institute of Dermatology, St Thomas' Hospital, London SE1 7EH, U.K.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Autoimmune Diseases / therapy*
Epidermolysis Bullosa Acquisita / therapy
Immunoglobulins, Intravenous / administration & dosage*
Middle Aged
Pemphigoid, Bullous / therapy
Retrospective Studies
Skin Diseases, Vesiculobullous / therapy*
Treatment Outcome
Reg. No./Substance:
0/Immunoglobulins, Intravenous
Comment In:
Br J Dermatol. 2000 Mar;142(3):582   [PMID:  10777275 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Characterization of the antibody response in oesophageal cicatricial pemphigoid.
Next Document:  The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma.